Licensing, Pharmaceuticals and Research

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Drug Patent Watch

DECEMBER 12, 2024

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies.

Licensing

Licensing Licensing Drugs Biosimilars

Collaboration aims to reduce animal use in drug safety testing

Broad Institute

JULY 29, 2025

The researchers are testing compounds on multiple cell models, and are now producing and sharing datasets from their first rounds of experiments. OASIS includes more than 50 partner groups and is two years into its initial three-year pilot phase.

Animal Testing

Animal Testing Drugs Science Pharmaceuticals

How do patent thickets vary across different countries

Drug Patent Watch

DECEMBER 10, 2024

“Patent thickets can lead to holdup of innovations, increases in the complexity of negotiations over licenses and increases in litigation, and can also create incentives to add more and weaker patents to the patent system. Cross-licensing agreements: To navigate patent thickets, many companies enter into cross-licensing agreements.

Licensing

Licensing Licensing International Marketing

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

JUNE 11, 2025

Multimodal language models Generative AI models (GenAI) in the pharmaceutical field have reached the highest level of attention with the Nobel Prizes to Demis Hassabis and John Jumper for AlphaFold, which can predict protein structures. This approach limits the transformative potential of the technology.

Drugs

Drugs Clinical Trials Drug Development Pharmaceuticals

Teva and Fosun Partner to Develop Novel Anti-PD1-IL2 Immunotherapy

The Pharma Data

JUNE 16, 2025

Teva and Fosun Pharma Forge Strategic Partnership to Develop and Commercialize Innovative Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology Teva Pharmaceutical Industries Ltd. and Shanghai Fosun Pharmaceutical (Group) Co., About Fosun Pharma (Shanghai Fosun Pharmaceutical (Group) Co.,

Therapies

Therapies Licensing Licensing Treatment

Pharmaceutical Negotiations Decoded: Lessons from the Trenches

Drug Patent Watch

JANUARY 14, 2025

In the fast-paced world of pharmaceuticals, negotiations play a pivotal role in shaping the industry’s landscape. From mergers and acquisitions to licensing agreements and pricing discussions, these complex interactions demand a unique blend of scientific knowledge, business acumen, and interpersonal skills.

Pharmaceuticals

Pharmaceuticals Compliance Licensing Licensing

Toxicology transformed: Why accuracy now leads the way

Drug Target Review

DECEMBER 11, 2024

As a contract research organisation, we have supported numerous clients in overcoming matrix interference, particularly small and emerging biotherapeutics developers who may lack the in-house expertise to navigate such complex problems. This highlights its vital role in modern biotherapeutic research.

International

International Laboratories Drugs Pharmacokinetics

Biotech leader champions targeted cancer treatments and diversity

Drug Target Review

NOVEMBER 25, 2024

I went on to complete my MBA and PhD at The Institute of Cancer Research (ICR) in drug development. At this point, I knew that I wanted to join the biotech and pharmaceutical industry, so I moved to a small biotech company in London, where I spent three to four years learning the fundamentals of the biotech industry.

Treatment

Treatment Small Molecule Clinical Trials Trials

Protein degraders: chasing undruggable targets

BioPharma Drive: Drug Pricing

JULY 8, 2025

Published July 8, 2025 Gwendolyn Wu Senior reporter post share post print email license Proteasomes are cellular machines for breaking down proteins. Multiple deals have been struck by large companies such as Roche and Novartis, suggesting pharmaceutical firms believe degraders have only begun to show their promise.

Targeted Protein Degradation

Targeted Protein Degradation Small Molecule Disease Therapies

Revolution Medicines Secures $2B Funding from Royalty Pharma for RAS(ON) Cancer Drug Development

The Pharma Data

JUNE 24, 2025

This dual-pronged approach allows Revolution Medicines to access capital tailored to its evolving needs without relinquishing equity or ceding commercial rights to a larger pharmaceutical partner. Source link

Drug Development

Drug Development Clinical Trials Therapies Drugs

Bayer Expands Collaboration with Tsinghua University to Boost Pharma R&D in China

The Pharma Data

JUNE 24, 2025

Bayer and Tsinghua University Deepen Strategic Alliance to Advance Pharmaceutical Innovation in China Bayer and Tsinghua University (THU), two powerhouses in global pharmaceutical innovation and academic research, have announced a renewed commitment to their long-standing partnership.

Pharma R&D

Pharma R&D Pharmaceutical Companies Pharmaceuticals Science

Otsuka’s Sibeprenlimab Shows Significant Proteinuria Reduction in Phase 3 IgAN Trial

The Pharma Data

JUNE 6, 2025

Otsuka Unveils Promising Phase 3 Results for Sibeprenlimab in IgA Nephropathy, Marking Significant Proteinuria Reduction and Advancing a Novel APRIL-Targeted Therapy Otsuka Pharmaceutical Development & Commercialization, Inc., in collaboration with Otsuka Pharmaceutical Co., Source link

Trials

Trials Treatment Therapies FDA

Nobel Prize celebrates AI’s role in protein structure innovation

Drug Target Review

DECEMBER 9, 2024

Since its launch, AlphaFold has accurately predicted the structure of over 200 million proteins and been used by more than 2 million researchers globally. The second half of the prize was awarded to David Baker, a structural biologist from the University of Washington, for his research in computational protein design.

Engineering

Engineering International Drug Development Science

2025 Merkin Prize in Biomedical Technology awarded to pioneers of CAR T-cell therapy

Broad Institute

MAY 21, 2025

The Merkin Prize recognizes novel technologies that have improved human health and is administered by the Broad Institute, one of the worlds leading biomedical research institutes. Some researchers suspected that the body would attack and destroy the CAR T cells. Their work puts us on the doorstep of finding cures to help millions.

Therapies

Therapies FDA Approval Engineering Immune Response

Obesity care gets personalised: tailoring therapies with Phenomix

Drug Target Review

MARCH 4, 2025

Phenomix Sciences, built on over a decade of clinical research at the Mayo Clinic, is disrupting this outdated approach. The research demonstrated that obesity is not one disease, but many; each of which should be treated with different interventions, says Bagnall. These individuals respond four times better to GLP-1 medications.

Therapies

Therapies Treatment Clinical Trials Science

Navigating Regulatory Hurdles in Drug Development

DrugBank

JUNE 18, 2025

While these regulations protect public health, they also introduce significant challenges for pharmaceutical researchers. This means pharmaceutical companies must remain vigilant and adaptable to comply with evolving regulations. The extensive data requirements for regulatory submissions further complicate the process.

Drug Development

Drug Development Clinical Trials Compliance Drugs

Royalty Pharma and Revolution Medicines Sign Funding Deals Worth Up to $2 Billion

The Pharma Data

JUNE 24, 2025

Rather than diluting ownership or yielding developmental control to a larger pharmaceutical partner, Revolution Medicines is leveraging this funding arrangement to maintain autonomy over its research, development, and eventual commercialization efforts.

Clinical Development

Clinical Development Packaging Therapies Treatment

Inavolisib

New Drug Approvals

APRIL 25, 2025

3] Research Due to inavolisibs ability to inhibit the PI3K pathway through HER2 -dependent degradation, it is undergoing clinical trials to potentially make use of it as an antineoplastic (anti-cancer) drug to treat breast cancer. [4] American Association for Cancer Research (AACR): PD414PD414. 3 November 2006. PMID 34127844.

FDA

FDA FDA Approval Therapies Trials

The future of mental health treatment: Zelquistinel’s role

Drug Target Review

MARCH 17, 2025

Advancing drug candidates across key therapeutic areas Dr John Donello brings over 25 years of experience in pharmaceutical drug discovery, development and collaborations. With over 25 years of experience in the pharmaceutical industry, Donello has been instrumental in drug discovery and development.

Treatment

Treatment Licensing Licensing Science

Vamorolone

New Drug Approvals

JULY 25, 2025

2] [3] Vamorolone is a novel and fully synthetic glucocorticoid developed by Santhera Pharmaceuticals. 10] Society and culture Legal status Santhera Pharmaceuticals signed an agreement with Catalyst Pharmaceuticals for the North American commercialization of vamorolone in July 2023. [20] 65 (9): 737–743. PMID 27261270.

FDA

FDA FDA Approval Treatment Clinical Trials

Suzetrigine

New Drug Approvals

APRIL 2, 2025

1] [2] It was developed by Vertex Pharmaceuticals , [5] and was approved for medical use in the United States in January 2025. [2] acting director of the FDA’s Center for Drug Evaluation and Research. The FDA granted approval of Journavx to Vertex Pharmaceuticals Incorporated. Suzetrigine is taken by mouth. [1]

FDA

FDA Therapies Trials Treatment

Why smarter financial planning could be key to clinical trial success

Drug Target Review

JULY 29, 2025

As the pharmaceutical and biotech industries continue to evolve, clinical trials become more complex, and the importance of robust financial oversight has never been clearer. Jennifer has been a licensed CPA (California) since July 2014. 1 These companies often have smaller budgets ranging from $30 million to $300 million per trial.

Clinical Trials

Clinical Trials Trials Clinical Development Drug Development

FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche

BioPharma Drive: Drug Pricing

JUNE 11, 2025

Published June 11, 2025 Ben Fidler Senior Editor post share post print email license The FDA on June 11, 2025 approved Nuvation's Ibtrozi for ROS1-positive non-small cell lung cancer. In a research note on Wednesday, RBC Capital Markets analyst Leonid Timashev estimated peak yearly sales of the drug could reach nearly $640 million.

FDA

FDA Drugs Therapies Science

Effective Drug Patent Prosecution Strategies: Securing Your Pharmaceutical Innovations

Drug Patent Watch

DECEMBER 18, 2024

As a business professional in the pharmaceutical industry, understanding and implementing effective strategies for drug patent prosecution can be the difference between market domination and missed opportunities. Dr. Jane Smith, a patent attorney specializing in pharmaceuticals, advises: “File early and file often. billion[1].

Pharmaceuticals

Pharmaceuticals Drugs Drug Development Marketing

Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks

BioPharma Drive: Drug Pricing

JULY 16, 2025

Published July 16, 2025 • Updated 2 hours ago Ben Fidler Senior Editor post share post print email license Sarepta Therapeutics announced a workforce reduction on July 16, 2025. In a statement Monday , Sarepta said it plans to cut approximately 36% of its staff and pause research on several drug programs. By Jonathan Gardner • Sept.

Therapies

Therapies FDA Clinical Trials Licensing

Soleno sales of new Prader-Willi drug rise faster than expected

BioPharma Drive: Drug Pricing

JULY 10, 2025

Published July 10, 2025 Ben Fidler Senior Editor post share post print email license Soleno Therapeutics on July 10, 2025 announced preliminary sales for its new Prader-Willi Syndrome drug Vykat. This database now covers the 50 best-selling pharmaceutical products and has been updated to reflect current patent expiry expectations.

Drugs

Drugs Licensing Licensing Therapies

Lexeo to help launch spinout around RNA drugs for the heart

BioPharma Drive: Drug Pricing

JUNE 24, 2025

Published June 24, 2025 Gwendolyn Wu Senior reporter post share post print email license Lexeo Therapeutics and two life sciences investors are working together to launch a startup to develop cardiac RNA therapies. By Jonathan Gardner • Sept. By Jonathan Gardner • Sept.

RNA

RNA Drugs Therapies Licensing

Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval

BioPharma Drive: Drug Pricing

JULY 30, 2025

Published July 30, 2025 Ned Pagliarulo Lead Editor post share post print email license Daniel Tadevosyan via Getty Images Today, a brief rundown of news involving Madrigal Pharmaceuticals and Viridian Therapeutics, as well as updates from Apellis Pharmaceuticals, PTC Therapeutics and Arrowhead Pharmaceuticals that you may have missed.

Drugs

Drugs Clinical Trials FDA Therapies

Merck to buy Verona and its lung drug in $10B deal

BioPharma Drive: Drug Pricing

JULY 9, 2025

Published July 9, 2025 By Kristin Jensen post share post print email license Merck & Co. logo displayed on the exterior of their research facility in San Francisco, Calif., But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.

Clinical Trials

Clinical Trials Drugs Therapies Licensing

Private equity firms back PCI Pharma in bet on drug production

BioPharma Drive: Drug Pricing

JULY 14, 2025

Published July 14, 2025 Ben Fidler Senior Editor post share post print email license Bain Capital, Kohlberg and Mubadala joined to invest in biopharmaceutical CDMO PCI Pharma on July 14, 2025. By Jonathan Gardner • Sept. 4, 2024 Keep up with the story. By Jonathan Gardner • Sept.

Production

Production Drugs Therapies Clinical Trials

Incyte replaces CEO Hoppenot with dealmaker Meury

BioPharma Drive: Drug Pricing

JUNE 26, 2025

Published June 26, 2025 Ned Pagliarulo Lead Editor post share post print email license An Incyte researcher works in a laboratory. However, it flamed out in testing in 2018 and Incyte was forced to pivot research toward other candidates. Since then, Incyte has had some success building out its portfolio.

Therapies

Therapies Licensing Licensing Vaccine

Optimizing Your Drug Patent Strategy: A Comprehensive Guide for Pharmaceutical Companies

Drug Patent Watch

JANUARY 8, 2025

With billions of dollars invested in research and development, protecting your intellectual property is not just importantit’s essential. Drug patents are a form of intellectual property protection that grants pharmaceutical companies exclusive rights to manufacture, sell, and profit from their innovations for a set period.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceuticals Licensing Licensing

Genmab Unveils Executive Committee Restructuring

The Pharma Data

JULY 2, 2025

Under Birgitte’s guidance, Genmab successfully navigated key licensing agreements, multiple strategic collaborations with leading pharmaceutical companies, and its listing on the Nasdaq Global Select Market.

Compliance

Compliance Pharmaceutical Companies Government International

Regulatory uncertainty and access challenges changing go-to-market models, DTC, and DTP

BioPharma Drive: Drug Pricing

AUGUST 11, 2025

GoodRx research shows an average 39% list price increase for all prescription medications since 2014, and in 2024 Americans paid $61 billion in OOP costs for their prescription medications. This burden persists despite the pharmaceutical industry investing over $5 billion annually in copay assistance and support programs.

Marketing

Marketing Pharmacy Therapies Clinical Trials

Trends in Pharmaceutical Mergers and Acquisitions

DrugBank

OCTOBER 4, 2024

Deal Structuring Deal structuring in pharmaceutical M&A requires a balance of financial, legal, and strategic considerations. Intellectual Property Valuation Valuing intellectual property (IP) assets is a critical component of pharmaceutical M&A, as these assets often represent a significant portion of a company's value.

Pharmaceuticals

Pharmaceuticals Pharmaceutical Companies Therapies Marketing

Replimune drug rejected by FDA; Omega raises $647M biotech fund

BioPharma Drive: Drug Pricing

JULY 22, 2025

Published July 22, 2025 By BioPharma Dive staff post share post print email license Daniel Tadevosyan via Getty Images Today, a brief rundown of news involving Replimune Group and Johnson & Johnson, as well as updates from Omega Funds, iTeos Therapeutics and Roche that you may have missed. and European life sciences companies.

FDA

FDA Specialty Pharmacies Drugs Therapies

Sanofi to acquire vaccine biotech in billion-dollar deal

BioPharma Drive: Drug Pricing

JULY 22, 2025

Published July 22, 2025 • Updated 2 hours ago Delilah Alvarado Staff Reporter post share post print email license A sign bearing Sanofi's logo sits outside the company's U.S. JHVE Photo via Getty Images Dive Brief: French pharmaceutical giant Sanofi said Tuesday it will pay $1.15 headquarters in Bridgewater, New Jersey.

Vaccine

Vaccine Clinical Trials FDA Therapies

Common Drugs with Effective Off-Label Uses

Drug Patent Watch

JULY 13, 2020

Mudawi in the Journal of Pharmaceutical Research International under the terms of the Creative Commons Attribution License.…. This article was originally published by Mohammed M. Alshehri and Mahmoud M. The post Common Drugs with Effective Off-Label Uses appeared first on DrugPatentWatch - Make Better Decisions.

Licensing

Licensing Licensing Drugs International

Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate

The Pharma Data

OCTOBER 27, 2021

Teva Pharmaceutical Industries Ltd. NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. Teva Pharmaceutical Industries Ltd. About Teva. Learn more at www.tevapharm.com.

Licensing

Licensing Licensing Disease Small Molecule

Hyman, Phelps & McNamara, P.C. (HP&M) is Pleased to Announce the Addition of Sara M. Keup as the new State Licensing Regulatory Expert for the Firm’s Licensing Practice

FDA Law Blog: Biosimilars

FEBRUARY 5, 2024

HP&M has been helping clients navigate the challenges of state licensing regulations for drugs, biologics, medical devices, OTCs, 503B outsourcing facilities, 503A pharmacies, foods, dietary supplements, cannabis, and wholesalers/distributors for many years. Keup has joined the firm to assist attorneys Karla L.

Licensing

Licensing Licensing Pharmacy Regulations

Allecra Therapeutics and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China

The Pharma Data

DECEMBER 20, 2020

Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties.

Licensing

Licensing Licensing Pharmaceuticals Pharmaceutical Companies

Looking for Opportunities to Accelerate Clinical Research in Rare Diseases

LifeSciVC

JULY 17, 2024

It’s important to recognize that for many large pharmaceutical and biotechnology companies, compounds that have the potential to treat a rare disease of significant unmet need might become lower strategic priority than those that have mass market potential.

Clinical Research

Clinical Research Disease Research Clinical Trials

“Thaw Out” with Pharma Thought Leaders at the 2024 Puerto Rico Pharmaceutical Summit: HPM Directors to Discuss Drug Approvals and Puerto Rico “Exportation” Best Practices

FDA Law Blog: Biosimilars

JANUARY 11, 2024

(HPM) Directors, Karla Palmer and Dara Levy , will present at the Puerto Rico Pharmaceutical Summit 2024, February 6, 2024, at the La Concha Renaissance San Juan Resort in San Juan, Puerto Rico. HPM is a co-sponsor of the event. The event is hosted by by Porzio, Bromberg & Newman. To register, please use this link.

Pharmaceuticals

Pharmaceuticals Licensing Licensing Compliance

For the Children: Advancing the Cause of Pediatric Cancer Research

Crown Bioscience

MAY 4, 2021

Crown Bioscience Director Mike Batey takes a closer look at pediatric cancer and how recent regulatory changes and additional research focus may deliver new therapies for kids. used in a way that is not described in the license), and only three drugs have been approved exclusively for use in children.

Research

Research Pharmaceutical Companies Licensing Licensing

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Collaboration aims to reduce animal use in drug safety testing

Trending Sources

How do patent thickets vary across different countries

From siloed data to breakthroughs: multimodal AI in drug discovery

Teva and Fosun Partner to Develop Novel Anti-PD1-IL2 Immunotherapy

Pharmaceutical Negotiations Decoded: Lessons from the Trenches

Toxicology transformed: Why accuracy now leads the way

Biotech leader champions targeted cancer treatments and diversity

Protein degraders: chasing undruggable targets

Revolution Medicines Secures $2B Funding from Royalty Pharma for RAS(ON) Cancer Drug Development

Bayer Expands Collaboration with Tsinghua University to Boost Pharma R&D in China

Otsuka’s Sibeprenlimab Shows Significant Proteinuria Reduction in Phase 3 IgAN Trial

Nobel Prize celebrates AI’s role in protein structure innovation

2025 Merkin Prize in Biomedical Technology awarded to pioneers of CAR T-cell therapy

Obesity care gets personalised: tailoring therapies with Phenomix

Navigating Regulatory Hurdles in Drug Development

Royalty Pharma and Revolution Medicines Sign Funding Deals Worth Up to $2 Billion

Inavolisib

The future of mental health treatment: Zelquistinel’s role

Vamorolone

Suzetrigine

Why smarter financial planning could be key to clinical trial success

FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche

Effective Drug Patent Prosecution Strategies: Securing Your Pharmaceutical Innovations

Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks

Soleno sales of new Prader-Willi drug rise faster than expected

Lexeo to help launch spinout around RNA drugs for the heart

Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval

Merck to buy Verona and its lung drug in $10B deal

Private equity firms back PCI Pharma in bet on drug production

Incyte replaces CEO Hoppenot with dealmaker Meury

Optimizing Your Drug Patent Strategy: A Comprehensive Guide for Pharmaceutical Companies

Genmab Unveils Executive Committee Restructuring

Regulatory uncertainty and access challenges changing go-to-market models, DTC, and DTP

Trends in Pharmaceutical Mergers and Acquisitions

Replimune drug rejected by FDA; Omega raises $647M biotech fund

Sanofi to acquire vaccine biotech in billion-dollar deal

Common Drugs with Effective Off-Label Uses

Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate

Hyman, Phelps & McNamara, P.C. (HP&M) is Pleased to Announce the Addition of Sara M. Keup as the new State Licensing Regulatory Expert for the Firm’s Licensing Practice

Allecra Therapeutics and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China

Looking for Opportunities to Accelerate Clinical Research in Rare Diseases

“Thaw Out” with Pharma Thought Leaders at the 2024 Puerto Rico Pharmaceutical Summit: HPM Directors to Discuss Drug Approvals and Puerto Rico “Exportation” Best Practices

For the Children: Advancing the Cause of Pediatric Cancer Research

Stay Connected